{"title":"A tumor-targeting nano-adjuvant for in situ vaccine based on ultrasound therapy","authors":"Linjie Cui, Haochen Yao, Fuxin Xue, Jiali Sun, Xitong Ren, Mengfei Zheng, Zhilin Liu, Zhaohui Tang","doi":"10.1002/agt2.504","DOIUrl":null,"url":null,"abstract":"<p>Ultrasound-generated antigens combined with TLR7/8 agonists as adjuvants have demonstrated significant anti-tumor efficacy as an in-situ vaccine. However, the use of TLR7/8 agonists can cause severe inflammatory responses. In this study, we present a novel tumor-targeting nano-adjuvant termed aPDL1-PLG/R848 NPs, which are composed of aPDL1 antibody, Fc-III-4C peptide linker (Fc-linker) and poly(<i><sub>L</sub></i>-glutamic acid)-<i>grafted</i>-R848. Under ultrasound irradiation, antigen-presenting cells activate immune mechanisms in vivo under dual stimulation of in situ antigens and immune adjuvants. The strategy inhibits primary tumor growth and induces a strong antigen-specific immune memory effect to prevent tumor recurrence in vivo. This work offers a safe and potent platform for an in situ cancer vaccine based on ultrasound therapy.</p>","PeriodicalId":72127,"journal":{"name":"Aggregate (Hoboken, N.J.)","volume":null,"pages":null},"PeriodicalIF":13.9000,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/agt2.504","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aggregate (Hoboken, N.J.)","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/agt2.504","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Ultrasound-generated antigens combined with TLR7/8 agonists as adjuvants have demonstrated significant anti-tumor efficacy as an in-situ vaccine. However, the use of TLR7/8 agonists can cause severe inflammatory responses. In this study, we present a novel tumor-targeting nano-adjuvant termed aPDL1-PLG/R848 NPs, which are composed of aPDL1 antibody, Fc-III-4C peptide linker (Fc-linker) and poly(L-glutamic acid)-grafted-R848. Under ultrasound irradiation, antigen-presenting cells activate immune mechanisms in vivo under dual stimulation of in situ antigens and immune adjuvants. The strategy inhibits primary tumor growth and induces a strong antigen-specific immune memory effect to prevent tumor recurrence in vivo. This work offers a safe and potent platform for an in situ cancer vaccine based on ultrasound therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
